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POLYMORPHISMS 
IN THE 5މ-UTR OF PTEN AND 
OTHER GENE POLYMORPHISMS 
IN NORMAL JAPANESE INDIVIDUALS 
Polymorphisms are distributed differently in popu-
lations, including those of regions, ethnic groups, and 
diseased patients. In order to investigate variation in 
nucleotide sequences in normal individuals, we isolated 
genomic DNA from the blood of healthy Japanese indi-
viduals and sequenced the 5މ-untranslated region (5މ-
UTR) of the phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) gene and the gene promoter, 
intron, and exon nucleotides of p53, p14ARF, murine double 
minute 2 (MDM2), and the ǃ2- and ǃ3-adrenoceptor
(-AR). We found polymorphisms in these regions, including 
a deletion at positions –465 to –463 and a substitution 
at position –404 in PTEN and a substitution at position 
–4924 in p14ARF, in normal individuals. Individuals with 
or without the PTEN polymorphism harbored a different 
distribution of polymorphisms, including simultaneous 
alterations in nucleotides of p53, MDM2, and ǃ3-AR, 
and also harbored some polymorphic nucleotides located 
in the same set of associatively altered nucleotides. Our 
results show that multiple nucleotides, including the PTEN 
nucleotides, are altered in normal Japanese individuals 
and provide useful information for genotyping studies in 
individuals and populations. 
Introduction. Control subjects harbor poly-
morphisms of the phosphatase and tensin homo-
log deleted on chromosome 10 (PTEN) gene,
including those at positions –1026, –903 [1], 
and –9 [2] in the 5މ-untranslated region (5މ-
UTR). The PTEN –1026 and –903 poly-
morphisms are located around the binding sites 
of transcription factors such as Sp1 [1], and the 
–9 polymorphism is located close to a Kozak 
sequence. A polymorphism of the p53 gene in 
codon 72, which is commonly found in various 
populations, including the Japanese population 
[3], is distributed latitude-dependently among 
resident populations of eastern Asia in areas 
located from 10–50° north; the distribution of 
this polymorphism is also associated with win-
ter temperatures [4]. In addition, an intron 
polymorphism at position SNP309 of the murine 
double minute 2 (MDM2) gene shows a different 
distribution among regions that are exposed to 
distinct levels of ultraviolet radiation [4]. A PTEN 
promoter polymorphism at position –1142, 
which is found in normal Japanese individuals, 
is located within a p53-binding element [5], 
and a p53 promoter polymorphism at the –824 
to –818 poly(C) positions (a C-to-C insertion 
polymorphism) found in a normal Japanese 
population [6] and the PTEN –1142 promoter 
polymorphism alter cellular transcriptional activity 
in the presence or absence of serum in culture 
medium [5]. PTEN gene expression is increased at 
32 °C in cells expressing a temperature-sensitive 
p53 mutant [7] and differs among individuals, 
including control subjects [1] and those with non-
diseased tissues [8, 9]. 
Polymorphisms are reportedly associated with
individual predispositions, including those to di-
seases. A population-based study using polyme-
rase chain reaction-single-strand conformational 
polymorphism (PCR-SSCP) and direct nucleo-
tide sequencing analyses has shown that the –9 
polymorphism in the PTEN 5މ-UTR is associated 
with a disease of diabetes exhibiting metabolic 
abnormalities in a Japanese population [2]. A 
similar association with diabetes has also been 
reported for other gene polymorphisms, including 
a p14ARF polymorphism at position –3735, in 
a European population [10]. Some promoter 
polymorphisms within the p14ARF 4.5 kb promoter, 
including the –3735 polymorphism, have been 
observed in an Asian (Korean) population [11]. 
Further, other association studies based on po-
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pulations or follow-up observations have shown 
that exon 1 polymorphisms of the ǃ2- and ǃ3-
adrenoceptor(-AR) genes at codons 27 and 64 
are associated with not only metabolic diseases, 
such as diabetes and obesity [12, 13], but also 
other diseases, such as hypertension [14] and 
cancers of the breast [15] and colon [16]. In such 
association studies, polymorphisms are observed 
in control subjects who do not suffer from disease 
and are not necessarily observed in all of the 
patients. 
Individuals, including non-cancer patients and 
normal individuals, harbor multiple nucleotide 
alterations in each gene; e.g., alterations in intron 
1, 3, 4, and 8 of the PTEN gene [17] or in exon 
1 at position –628 and intron 1 at positions –466 
and –215 (SNP309) of the MDM2 gene [6]. The 
MDM2 –628 and –466 polymorphisms observed 
in normal Japanese individuals are included in 
associative alterations in nucleotides [6], and 
the PTEN intron 1, 3, 4, and 8 polymorphisms 
observed in individuals, including non-cancer 
patients, are involved in a highly linked sequence 
of nucleotides [17]. The SNP309 polymorphism 
of MDM2 is reportedly in linkage disequilibrium 
with other polymorphisms of MDM2 and is 
distributed differently between ethnic groups 
[18]. Similar linkage has also been shown for 
the p14ARF promoter polymorphisms in a Korean 
population [11]. An association study has reported 
that the presence of the –9 polymorphism of 
the PTEN 5މ-UTR decreases the risk of some 
carcinomas in the absence of another PTEN 
intronic polymorphism (a sequence insertion of 
five nucleotides) in a Chinese population [19]. 
Polymorphic nucleotides linked with other 
polymorphisms are useful for genotyping studies 
in populations. 
In the present study, in order to investigate 
whether normal individuals harbor other PTEN 
polymorphisms and whether each individual 
harbors multiple nucleotide alterations, we 
isolated genomic DNA from the blood of healthy 
Japanese individuals and sequenced the 5މ-UTR 
of PTEN together with other gene promoter, 
intron, and exon nucleotides at positions –824 to 
–818 of p53; position –3735 of p14ARF; positions 
–628, –466, and –215 (SNP309) of MDM2; 
and codons 27 and 64 of ǃ2- and ǃ3-AR. We 
also sequenced the nucleotides upstream of the 
p14ARF 4.5 kb promoter sequence and searched 
polymorphic nucleotides associatively altered with
other p14ARF polymorphisms. 
Materials and methods. Study subjects and geno-
mic DNA extraction. Human peripheral blood was 
obtained from 21 healthy Japanese students (in 
which male students outnumber female students)
in their early twenties who consented to have 
their DNA sequenced for identification of poly-
morphisms. Genomic DNA was extracted from 
whole blood with a QIAamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany). DNA analysis showed 
that the frequency of a known polymorphism 
(NAD(P)H:quinone oxidoreductase (NQO1) poly-
morphism (C609T); [20]) was similar to that 
previously found in control Japanese subjects 
(the frequency of the NQO1 polymorphism was 
48 % homozygous C/C, 38 % heterozygous C/T, 
and 14 % homozygous T/T). We investigated 
the frequency of the examined polymorphism by 
using samples obtained from 12 randomly selec-
ted students (the polymorphic frequency of 
NQO1 was 58.3 % homozygous C/C, 33.3 % 
heterozygous C/T, and 8.3 % homozygous T/T), 
and these randomly selected samples (seven in-
dividual samples in the case of the p14ARF pro-
moter) were used to identify polymorphisms. 
PCR amplification. The PTEN 5މ-UTR and the 
promoter sequence of p14ARF were amplified by 
PCR in a reaction mixture containing genomic 
DNA (0.1 g), a primer set (Table 1), and DNA 
polymerase (KOD-Plus DNA polymerase ([21]; 
Toyobo, Osaka, Japan) for PTEN or PfuTurbo 
DNA polymerase ([22]; Stratagene, La Jolla, 
CA) for p14ARF) according to the manufacturer’s 
instructions. Amplification was performed in 
a thermal cycler (Takara PCR Thermal Cycler 
MP; Takara Bio, Osaka, Japan) under the 
following conditions: denaturation at 94 °C for 
15–30 s, annealing at melting temperature [Tm] 
– 5 °C for 1 min, and extension at 68–72 °C 
for 2 min. For the promoter, intron, and exon 
regions of p53 and MDM2, PCR amplification 
was performed by using a primer set (Table 1)
as described previously [6]. For the exon re-
gions of ǃ2- and ǃ3-AR, PCR was performed by 
using the following primers as described previ-
ously [15, 23]: ǃ2-AR (forward primer: 5މ-GAA-
TGAGGCTTCCAGGCGTC-3މ; reverse primer: 
5މ-GGCCCATGACCAGATCAGCA-3މ) and ǃ3-
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AR (forward primer: 5މ-CGCCCAATACCG-
CCAACAC-3މ; reverse primer: 5މ-CCACCAG-
GAGTCCCATCACC-3މ). 
Determination of nucleotide sequences and ana-
lysis for polymorphisms. DNA amplified by PCR 
(PCR products) was used for sequence reactions 
(for PTEN, p14ARF, p53, and MDM2) to deter-
mine the polymorphic nucleotides. The sequence 
reactions were performed using an ABI PRISM 
Dye Terminator Cycle Sequencing Kit (Perkin-
Elmer Biosystems, Foster City, CA, USA), and 
nucleotide sequences were determined using an 
ABI PRISM 377 automated DNA sequencer 
(Perkin-Elmer Biosystems). The nucleotide sequ-
ences were compared with DNA sequences (ac-
cession nos. AF067844, AF082338.1, X54156.1, 
and U39736.1) in the DNA database of NCBI 
GenBank by using the basic local alignment 
search tool (BLAST; [24]). For the detection of 
sequence alterations, nucleotides were compared 
among individuals by using the sequence align-
ment editor program BioEdit (http://www.mbio.
ncsu.edu/BioEdit/bioedit.html), and heterozygo-
us nucleotide sequences were analyzed in detail by 
changing the horizontal scale for the alignments 
of allelic nucleotides. 
Detection of restriction fragment length polymor-
phisms (RFLPs) of ǃ2- and ǃ3-AR. PCR products 
were treated with or without a restriction enzyme 
(Fnu4HI; New England Biolabs, Inc., Ipswich, 
MA, USA (for ǃ2-AR) or BstOI; Promega, 
Madison, WI, USA (for ǃ3-AR)) for 2 h at 37 °C
in NEBuffer (New England Biolabs, Inc.) con-
taining bovine serum albumin according to the 
Table 1 
Primers used for PCR and sequencing 
Primer position1 Oligonucleotide primer
PTEN
–1530 to –1507
–845 to –822
–605 to –628
–375 to –398
–247 to –270
–33 to –56
p14ARF
–5322 to –5300 
–5009 to –4987 
–4050 to –4028
–4773 to –4794
–3267 to –3289
–2986 to –2965
–2702 to –2682
–2300 to –2279 
–2532 to –2553 
–2157 to –2178
p53
–918 to –899
–669 to –690
MDM2
–725 to –704
–310 to –289
+96 to +75 
5މ-TCTGCGAACGATTGTGATCCGACA-3މ 
5މ-AGTTCTCTCCTCTCGGAAGCTGCA-3މ
5މ-GAGGAAGAGGCTGCACGGTTAGAA-3މ 
5މ-GCCGCCGTGTTGGAGGCAGTAGAA-3މ
5މ-AGAAGACGAATAATCCTCCGAACG-3މ 
5މ-AGAGAGATGGCAGAAGCTGCTGGT-3މ
5މ-GTCTCCTCACAAGCATGTCAATC-3މ
5މ-GTTACATACATGAGTTATAGGAA-3މ 
5މ-CTGGCTCTTGCTGGCCATGAAGT-3މ 
5މ-GGCAGCATTACAATATCTAGTC-3މ
5މ-CTTCAACTGCTTGGATGAGGACC-3މ
5މ-CTGGATAACGATGCTTCAGTCA-3މ
5މ-TGTATATGATGTTTGCACAAC-3މ
5މ-TACAGAGGCGGAGGCCGGCTGA-3
5މ-CTATATCAGTCAGTTCTCCAGG-3މ
5މ-TACTTATGTACTTGTTTACTTG-3މ 
5މ-GCTGGGAGTTGTAGTCTGAA-3މ 
5މ-CATTGTTGTATTCCTGAGTGCC-3މ
5މ-TCTGACCGAGATCCTGCTGCTT-3މ 
5މ-TTCGGACGGCTCTCGCGGCGGT-3މ 
5މ-AAGCTACAAGCAAGTCGGTGCT-3މ
Indications. 1Nucleotide positions are numbered by considering the position of nucleotide A at the ini-
tiation site for translation in PTEN (accession no. AF067844), nucleotide G [56] in p14ARF (accession 
no. AF082338.1), nucleotide G [57] in p53 (accession no. X54156.1), and nucleotide C at the 5މ end of exon 2 
[58] in MDM2 (accession no. U39736.1) as +1.
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manufacturer’s protocol and separated by 3 % 
agarose gel electrophoresis. RFLPs were detected 
by using ethidium bromide and ultraviolet light, 
and we evaluated the sizes of the DNA fragments 
generated by treatment with or without the 
restriction enzyme; ǃ2-AR Gln/Gln at codon 27 
produces 174-, 97-, 55-, and 27-bp fragments 
and Gln/Glu at codon 27 produces 229-, 174-, 
97-, 55-, and 27-bp fragments, and ǃ3-AR Trp/
Trp at codon 64 produces 99-, 62-, and 30-bp 
fragments and Trp/Arg at codon 64 produces 
161-, 99-, 62-, and 30-bp fragments. 
Results. PTEN polymorphisms and nucleotide 
sequence variations in normal Japanese individuals. 
We sequenced the 5މ-UTR upstream of the –9 
position of PTEN and further determined other 
nucleotides in the promoter, intron, and exon 
regions of p53, p14ARF , MDM2, and ǃ2- and ǃ3-AR.
We detected polymorphisms in the PTEN 5މ-
UTR (Figs 1–3, look a pasting in at the end of 
number) and in the other examined genes (Fig. 
4, look a pasting in at the end of number and 
Tables 2 and 3) in normal Japanese individuals, 
and we observed individual differences in these 
sequences (Tables 2 and 3). These sequence 
variations comprised deleted, substituted, and 
inserted nucleotides. In the PTEN 5މ-UTR, 
we found a deletion of nucleotide G (Fig. 1) 
(nucleotide C in the opposite DNA strand to 
the 5މ-UTR sequence; Fig. 2) at positions –465 
and –463 and a nucleotide substitution of C 
to T (Fig. 1) (G to A in the opposite strand 
to the 5މ-UTR; Fig. 3) at position –404; these 
polymorphisms were observed in individuals I and 
VIII, respectively (Table. 2). These individuals 
also harbored a C-to-C insertion at the –824 to 
–818 poly(C) positions of p53 (Fig. A.1, http://
cytgen.com/articles/4620024s.pdf) and a Trp-to-
Arg substitution at codon 64 of ǃ3-AR (Fig. A.3b) 
together with A-to-G and C-to-T substitutions 
at positions –628 and –466 (Fig. A.2 a and 
b) or a T-to-G substitution at position –215 
(SNP309) of MDM2 (Fig. A.2c) (Table 2). A 
Gln-to-Glu substitution of ǃ2-AR at codon 27 
(Fig. A.3a) was only observed in individual III, 
and this individual also harbored the p53 poly(C) 
and MDM2 SNP309 polymorphisms (Table 2). 
The ǃ3-AR codon 64 polymorphism and the p53 
and MDM2 polymorphisms were simultaneously 
found in individuals VII and XI, in addition to 
I and VIII, while other individuals (II, IV–VI, 
IX, X, and XII) harbored a polymorphism(s) 
in p53 and/or MDM2 (Table 2). An A-to-C 
substitution in p14ARF at position –3735 was 
not observed in any individuals (Table 2). The 
polymorphic nucleotides in PTEN, p53, MDM2, 
and ǃ2- and ǃ3-AR were not identical among 
all normal Japanese individuals (Table 2), but 
these individuals possessed the same set of 
associatively altered nucleotides at the MDM2 
polymorphic positions –628 in exon 1 and –466 
in intron 1 (the nucleotides shown as italics in 
Table 2). We also found a C-to-T substitution in 
p14ARF at position –4924 (Fig. 4) by sequencing 
the nucleotides upstream of the p14ARF 4.5 kb 
promoters in normal individuals. Similarly, the 
–4924 polymorphism of p14ARF was located in 
associative alterations in nucleotides (types D-J 
in Table 3) with other p14ARF polymorphisms at 
positions –2610 (an A-to-T substitution; Fig. 
A.4a–c) and –2221 to –2218 (an AA deletion; 
Fig. A.4d–f); the frequency of nucleotide types 
Į–J was 28.6 %, 57.1 %, and 14.3 %, respectively 
(Table 3). 
Discussion. Gene nucleotide alterations and 
their frequency distributions have been analyzed 
in various populations, including different re-
gions, ethnic groups, and patients with diseases; 
however, the nucleotide variations in normal 
individuals are not still understood sufficiently. 
Some PTEN polymorphisms have been observed 
in control populations [17, 2, 1, 19]. In Japanese 
or Chinese control subjects without diabetes or 
carcinomas, the frequency of the PTEN 5މ-UTR 
–9 polymorphism (nucleotide G) is 2.5 % [2] 
and 6.5 % [19], respectively. This polymorphism 
is also detected in a Turkish population with 
glioblastoma multiforme (GBM) [25], but it is not 
found in a Danish Caucasian population, where 
some intron polymorphisms have been identified 
and association studies for diabetes have been 
conducted [26]. We found other PTEN 5މ-UTR 
polymorphisms at positions –465 to –463 and 
position –404 in normal Japanese individuals 
(Figs 1–3), and we observed these polymorphisms 
in 1 (4.2 %) and 2 (8.3 %) alleles, respectively, of 
24 alleles (Table 2). The frequency of these PTEN 
polymorphisms was approximately similar to the 
frequency of the PTEN 5މ-UTR –9 polymorphism 
(2.5 %; [2]) in non-diabetic Japanese subjects 
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or the PTEN –1142 polymorphism in normal 
Japanese individuals (5.9%; [5]). Normal 
Japanese individuals, including individuals I and 
VIII with the PTEN 5މ-UTR polymorphisms 
at positions –465 to –463 and –404, harbored 
an insertion in the p53 promoter at the –824 to 
–818 poly(C) positions; substitutions in MDM2 
exon 1 and intron 1 at positions –628, –466, and 
–215 (SNP309) and in ȕ2- and ȕ3-AR exon 1 at 
codons 27 and 64; and a substitution or deletion 
in p14ARF at positions –4924, –2610, and –2221 
to –2218 (Tables 2 and 3). The frequency of the 
p53, MDM2, and ȕ2- and ȕ3-AR polymorphisms 
was not markedly different from that previously 
observed in normal Japanese individuals [6] and 
control subjects who visited Japanese hospitals 
for a checkup [27, 12, 13, 15]. The –3735 
polymorphism of p14ARF was not observed in our 
normal Japanese individuals (Table 2), and a 
Korean population had this polymorphism at a 
low frequency (0.03 %; [11]). The ȕ2-AR codon 
27 and ȕ3-AR codon 64 polymorphisms are 
observed in various races, including Asians [13], 
Europeans [23, 28], and Caucasians [29]. The 
ȕ2-AR codon 27 polymorphism is observed at a 
higher frequency in Caucasian populations, but the 
frequency of the ȕ3-AR codon 64 polymorphism 
is similar to that observed in African-American 
and Hispanic-Latino populations [30]. Further, 
the MDM2 SNP309 polymorphism is distributed 
differently between populations, including in 
patients and non-diseased patients [27], distinct 
regions [4], and ethnic groups [31, 18]. Some 
polymorphic nucleotides, including those of 
p14ARF at positions –4256, –3631 and –1477, are 
located in associatively altered nucleotides in a 
Korean population [11]. Normal Japanese in-
dividuals harbor simultaneous alterations, inclu-
ding those in the PTEN promoter at position 
–1124 and the p15INK4b (a cyclin-dependent kinase 
Table 2
PTEN, p53, p14ARF, MDM2, and ǃ2- and ǃ3-AR polymorphisms
Individual
number
PTEN PTEN p53 MDM2 MDM2 MDM2 ǃ2-AR ǃ3-AR p14ARF
5މ-UTR 5މ-UTR Promoter Exon 1 Intron 1 Intron 1 Exon 1 Exon 1 Promoter
–465 to –463 –404 –824 to –818 –6281 –4661 –215 codon 27 codon 64 –3735
I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII
3G/2G
3G/3G
3G/3G
3G/3G
3G/3G
3G/3G
3G/3G
3G/3G
3G/3G
3G/3G
3G/3G
3G/3G
C/C
C/C
C/C
C/C
C/C
C/C
C/C
T/T
C/C 
C/C 
C/C 
C/C
7C/8C
7C/8C 
7C/8C 
7C/8C 
7C/7C
7C/8C 
7C/8C 
7C/8C
7C/7C
7C/7C
8C/8C 
8C/8C
A/G
A/A
A/A 
A/A 
A/A
A/G 
A/G
A/A
A/G 
G/G
A/A 
A/A
C/T 
C/C
C/C 
C/C 
C/C
C/T 
C/T 
C/C 
C/T 
T/T
C/C 
C/C
T/T
G/G
G/G
T/T 
T/G 
T/T 
T/T 
G/G 
T/G 
T/T 
G/G 
G/G
Gln/Gln 
Gln/Gln 
Gln/Glu 
Gln/Gln 
Gln/Gln 
Gln/Gln 
Gln/Gln 
Gln/Gln 
Gln/Gln 
Gln/Gln 
Gln/Gln 
Gln/Gln
Trp/Arg 
Trp/Trp
Trp/Trp 
Trp/Trp 
Trp/Trp 
Trp/Trp
Trp/Arg 
Trp/Arg 
Trp/Trp 
Trp/Trp 
Trp/Arg 
Trp/Trp
A/A 
A/A 
A/A 
A/A 
A/A 
A/A 
A/A 
A/A 
A/A 
A/A 
A/A 
A/A
Indications. Nucleotide sequences were determined by direct sequencing of PCR products or by digesting 
PCR products with a restriction enzyme. The sequencing reactions were performed with the primers for PTEN 
(positions –375 to –398 and –247 to –270), p53 (positions –669 to –690), p14ARF (positions –4050 to –4028), 
and MDM2 (positions –725 to –704 and –310 to –289) (Table 1), and the digested products were separated and 
detected on agarose gels. 3G and 2G show PTEN nucleotides GGG and GG, respectively, at positions –465 to 
–463, and 7C and 8C show p53 poly(C) nucleotides CCCCCCC and CCCCCCCC, respectively, at positions 
–824 to –818. ǃ2-AR Gln/Gln and ǃ3-AR Trp/Trp express homozygous amino acids glutamine at codon 27 
and tryptophan at codon 64, respectively. ǃ2-AR Gln/Glu and ǃ3-AR Trp/Arg show heterozygous nucleotides 
consisting of glutamine and glutamic acid at codon 27 and of tryptophan and arginine at codon 64, respectively. 
1The characters in italics indicate nucleotides that are included in a set of associatively altered nucleotides.
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(CDK) inhibitor) promoter at position –699 
[5] or in the p53 promoter at the poly(C) 
positions and the MDM2 exon 1 and intron 2 
nucleotides at positions –628 and –466 [6]. 
Correspondingly, most of the normal Japanese 
individuals examined in the present study had 
simultaneously polymorphisms at t2 positions in 
PTEN, p53, p14ARF , MDM2, and ǃ2- and ǃ3-AR 
(Tables 2 and 3). In the present study, healthy 
Japanese individuals harbored polymorphisms in 
the PTEN 5މ-UTR at positions –465 to –463 and 
–404 together with other polymorphisms in the 
promoter, intron, and exon regions of the other 
genes, and individual nucleotide alterations were 
distributed differently in the Japanese individuals. 
In addition, these individuals harbored some 
polymorphic nucleotides located in the same set
of associatively altered nucleotides at positions, 
including positions –4929, –2610, and –2221 
to –2218 of p14ARF . Our results provide helpful
information for studies investigating the distribu-
tion of polymorphisms in different populations, 
including those of regions, races, and patients, 
and normal individuals. 
The identification of common polymorphism 
patterns in the human genome has been pursued
by the research community [32]. In a Korean 
population, some polymorphic positions in the
p14ARF promoter, including position –3631, are 
included in a haplotype block (a set of sin-
gle-nucleotide polymorphism (SNP)alleles in a
chromosomal region) [11]. Polymorphisms loca-
ted in a haplotype block are useful for genotyping 
studies in populations with similar polymorphic 
alleles. The polymorphic nucleotides of MDM2 at 
positions –628 and –466 observed in our Ja-
panese samples were located in the same set 
of associative nucleotide alterations (Table 2), 
similar to those previously observed in normal 
Japanese individuals [6]. Likewise, the p14ARF 
–4924 polymorphism found in our samples was 
located in such a set of associatively altered 
nucleotides with other p14ARF polymorphisms 
Table 3 
p14ARF polymorphic nucleotides associatively altered 
in normal Japanese individuals
Polimor-
phic types
p14ARF Frequ-
ency, 
%–4924 –26101 –2218 to –22211
Type D
Type E
Type J
C/C 
C/T 
T/T
A/A 
A/T 
T/T
4A/4A 
4A/2A
2A/2A
28.6 
57.1
14.3
Indications. 1Genomic DNA was amplified by PCR 
with forward primers at positions –2986 to –2965 
and –2702 to –2682 and reverse primers at 
positions –2532 to –2553 and –2157 to –2178. 
The nucleotide sequences were determined by direct 
sequencing of the PCR products; the sequencing 
reactions were performed with the primers at posi-
tions –2702 to –2682 and –2300 to –2279. 4A and 
2A show p14ARF polymorphic nucleotides AAAA and 
AA, respectively, at positions –2218 to –2221.
Fig. 1. Polymorphic nucleotides located in the PTEN 5މ-UTR. Nucleotide alterations found in normal individuals 
are indicated by bold italics (GGG or GG at positions –465 to –463 (a G deletion) and C or T at position –404 
(a C-to-T substitution)) in the alignment of the PTEN 5މ-UTR sequence deposited in GenBank (accession 
no. AF067844). The underlined GG dinucleotides show the distribution of the putative G-quadruplex sequences 
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(Table 3). On the other hand, the PTEN 
polymorphisms at positions –465 to –463 and 
–404 were not involved in the set of associative 
alterations (Table 2). This result appears to 
contrast with previous results observed by the 
PTEN intronic polymorphisms in non-cancer 
patients and tumor patients [17]. Polymorphic 
nucleotides associatively altered in individuals 
may be distributed differently within gene re-
gions. The strength of linkage disequilibrium of 
the MDM2 SNP309 polymorphism with other 
MDM2 polymorphisms differs between Ashkenazi 
Jewish, Caucasian, and African-American popu-
lations [18]. The polymorphisms, including the 
PTEN polymorphisms, found in the current 
study may be candidate polymorphisms for the 
construction of common polymorphism patterns 
in populations, including other ethnic groups and
diseased patients. Further investigations with a 
larger number of samples are needed to deter-
mine the degree of linkage strength among poly-
morphisms in populations. 
Gene transcript analysis with a reporter gene 
revealed that deletion of a region of the PTEN 
5މ-UTR sequence alters reporter gene expression 
in HEK293 cells [33]. The cellular senescence-
inhibited gene (CSIG) binds to PTEN mRNA, 
and inhibition of CSIG gene expression by using 
small interfering RNA modifies the change in 
reporter expression following insertion of the 
PTEN 5މ-UTR [33]. In Cos1 cells or Rat1 
fibroblasts overexpressing insulin receptors, the 
PTEN protein level and the molecular response 
of Akt, a protein kinase, to treatment with insulin 
are differentially induced by the PTEN –9 poly-
morphism [2]. The alignment of G-quadruplex 
nucleotides binds to cellular proteins [34] and 
can regulate cellular gene expression [35–37]. A 
search for G-quadruplex motifs by using the 
GRSDB2 database ([38]; http://bioinformatics.
ramapo.edu/GQRS/) showed that the PTEN poly-
morphisms are located within or around a G-
quadruplex sequence (which is indicated by the 
underlined nucleotides GG in Fig. 1). A 5މ-UTR 
polymorphism in BRCA2 at position –26 repor-
tedly alters the RNA secondary structure of the 
5މ-UTR and changes gene transcription activity 
in HeLa and MCF-7 cells [39]. The 5މ-UTR 
nucleotides around the PTEN polymorphisms at 
positions –465 to –463 are partially included in the 
alignment of the 5މ-GGGGAGGGGG-3މ sequence 
motif [40] or the 5މ-GAGGAGGGGG-3މ motif 
[41] located in a gene regulatory region for 
platelet-derived growth factor A-chain [40] or 
tissue inhibitor of metalloproteinase 2 (TIMP2) 
[41]; the TIMP2 sequence motif can interact 
with the Sp1 and Sp3 transcription factors [41]. 
We searched for transcription factors that can 
bind to sequences around the identified PTEN 
polymorphisms by using the TFSEARCH program 
(Searching Transcription Factor Binding Sites; 
http://mbs.cbrc.jp/research/db/TFSEARCH.
html) with a matrix similarity of >0.7. We also 
predicted the RNA secondary structure of 
the PTEN 5މ-UTR (from position –1031 to 
position –9; accession no. AF067844) with the 
CENTROIDFOLD program ([42]; http://www.
ncrna.org/centroidfold/). TFSEARCH database 
analysis revealed that the PTEN polymorphisms 
affected the similarity of sequences of the sub-
strates for putative transcription factors, for 
example, the similarity for MZF [43] at deleted 
nucleotide positions –465 to –463 and that for 
c-Rel [44] at substituted nucleotide position –404
in PTEN; similar results were also obtained by 
other polymorphisms (in a matrix similarity of 
>0.65), which affected, e.g., the similarity for 
TATA-binding protein at substituted or deleted 
positions –4924, –2610, and –2221 to –2218 
in p14ARF. Computational assessment with the 
CENTROIDFOLD program showed that the 
RNA structure was partially altered by the PTEN 
polymorphisms (Fig. A.5a–c). Similarly, the 
PTEN 5މ-UTR –9 polymorphism changed the 
similarity for certain transcription factors (e.g., 
p300; [45]) and partially altered the structure of the 
5މ-UTR (Fig. A.5 a and d). These results indicate 
that the polymorphisms, including the PTEN poly-
morphisms, can change the binding ability of 
known transcription factors to the regulatory 
regions and that the PTEN polymorphisms can 
influence the interactions of complementary nu-
cleotide sequences. 
PTEN is differentially expressed in control 
subjects [1] and non-tumor tissues [8, 9], and 
PTEN gene expression has been reported to differ 
among patients, including those with Cowden 
syndrome, an autosomal dominant disorder 
[1], and in individual mononuclear cells from 
bone marrow or peripheral blood obtained from 
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patients with normal acute myeloid leukemia 
([46]; data shown in accession no. GSE12417 in 
the NCBI Gene Expression Omnibus database). 
Gene expression analysis with the Cancer Geno-
me Atlas ([47]; http://cancergenome.nih.gov/) has 
shown that PTEN levels differ among patients 
with cancer, including those with GBM; a 
number of patients with cancer harbor somatic 
mutations in the exonic regions of the gene; 
however, other patients show different gene 
expression levels in the absence of these mutations. 
The mechanisms underlying the variable ex-
pression of PTEN among normal individuals and 
patients with disease remain unclear. The PTEN 
nucleotide alterations at polymorphic positions 
change transcription factor binding and affect 
nucleotide-nucleotide interactions in silico, and 
PTEN mRNA interacts with cellular protein 
that can alter gene expression depending on the 
sequence of the PTEN 5މ-UTR [33]. Our results 
provide possible clues for clarifying the molecular 
machinery underlying the gene expression ob-
served in individuals, including patients. 
The polymorphisms of MDM2 at position 
SNP309, of ǃ2- and ǃ3-AR at codons 27 and 64, and 
of p53 at codon 72 are associated with individual 
predisposition to diseases such as diabetes [12, 
23, 48] and carcinomas [49, 27, 15, 16] in various 
populations, including the Japanese population. 
The frequency of the ǃ2-AR polymorphism Gln/
Glu at codon 27 is increased in Caucasian 
females with obesity, but is decreased in obese 
males [29]. The ǃ3-AR polymorphism Trp/Arg 
at codon 64 is associated with cardiovascular 
risk factors in obese Hungarian children [28]. 
The p14ARF polymorphism at position –3631 has 
been associated with breast cancer in a British 
population [50], while the p14ARF polymorphism 
at –3735 is associated with diabetes in a French 
population with Europid ancestry [10]. The 
risk of chemical poisoning is associated with a 
polymorphism in intron 1 of p14ARF [51] and 
the risk of developing tumors is associated with 
a polymorphism in intron 4 of PTEN [19] in a 
Chinese population, and these associations have 
been shown to be dependent on the presence 
of another promoter polymorphism (Del1518) 
in the MDM2 gene [51] and the absence of the 
5މ-UTR –9 polymorphism in the PTEN gene 
[19], respectively. The simultaneous presence of 
other polymorphisms has also been shown to alter 
the degree of disease risk by gene polymorphisms 
[15, 49, 39]. Normal Japanese individuals did 
not harbor the p14ARF –3735 polymorphism, but 
harbored polymorphisms in the PTEN 5މ-UTR, 
in the promoter poly(C) nucleotides of p53 and 
other promoter nucleotides of p14ARF, and in 
intron 1 and exon 1 of MDM2 and ǃ2- and ǃ3-AR 
(Tables 2 and 3). Individuals II, III, VI, VII, and 
IX–XII harbored some simultaneous alterations 
in MDM2, ǃ2- and ǃ3-AR, and p53 (Table 2), 
while individuals IV and V harbored either 
the p53 poly(C) polymorphism or the MDM2 
SNP309 polymorphism, respectively (Table 2). 
Methyl-cytosine-phospho-guanine(CpG) sequen-
ces induced by DNA methyltransferases interact 
with methyl-CpG binding proteins and modulate 
cellular gene expression [52]. The SNP309 poly-
morphism of MDM2 is adjacent to a CpG se-
quence. Aditionally the cellular responses of ǃ2- 
or ǃ3-AR to an agonist for each receptor differ in 
individuals with the ǃ2-AR codon 27 polymorphism 
[53] or the ǃ3-AR codon 64 polymorphism 
[54]. Individuals I and VIII, with the PTEN 
polymorphisms, harbored simultaneously the p53, 
MDM2, and ǃ3-AR polymorphisms (Table 2). A 
C-to-T substitution (C609T) in NQO1, which 
was commonly observed in our individuals, has 
been associated with promoter methylation of the 
O6-methylguanine-DNA methyltransferase and 
p16INK4a (another CDK inhibitor) genes [55]. 
In our individual samples, the nucleotide A 
in the p16INK4a promoter at position –191 was 
substituted for nucleotide G, which is located 
within the CpG sequence (Fig. A.6 c and d). 
The –191 polymorphism was located in some 
individuals with the PTEN, MDM2, p53, or ǃ3-AR 
polymorphism, and the polymorphic frequency 
of p16INK4a was similar to that of NQO1 observed 
in our samples. Furthermore, the p16INK4a –191 
polymorphism (Fig. A.6 c and d) and the p14ARF 
–4924 (Fig. 4 b and c), –3631 (Fig. A.6 a 
and b), –2610 (Fig. A.4 b and c), and –2218 
to –2221 (Fig. A.4 e and f) polymorphisms 
were observed in normal individuals, including 
individual I harboring four polymorphisms and 
individual IV harboring one polymorphism 
(Table A.1 and some data not shown). In 
follow-up studies and population-based studies 
to determine the association of polymorphisms 
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to individual predispositions, polymorphisms are 
useful markers of an individual’s constitution and 
as information for personalized medicine. Our 
findings provide useful information for studies on 
the determination of polymorphism patterns that 
exhibit an individual’s predisposition, including 
disease, and contribute to a better understanding 
of individual nucleotide variations. Further stu-
dies are needed to clarify individual differences in 
nucleotide sequences. 
In the present study, we have shown that 
polymorphisms are observed in healthy Japanese 
individuals, including those at positions –465 to 
–463 and –404 of PTEN and position –4924 of 
p14ARF , and that these individuals have a different 
distribution of polymorphisms in the 5މ-UTR, 
promoter, intron, and exon regions of PTEN, 
p53, p14ARF , MDM2, ǃ2- and ǃ3-AR and also har-
bor some polymorphic nucleotides located in the 
same set of associative nucleotide alterations. 
Most of the individuals with a nucleotide alte-
ration harbored other polymorphisms. Our results 
show that multiple nucleotides, including the 
PTEN nucleotides, are altered in healthy Japanese 
individuals and provide useful information for 
genotyping studies in individuals and populations. 
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ÏÎËÈÌÎÐÔÈÇÌ 5މ-UTR ÃÅÍÀ PTEN È 
ÄÐÓÃÈÅ ÃÅÍÍÛÅ ÏÎËÈÌÎÐÔÈÇÌÛ ÑÐÅÄÈ 
ÇÄÎÐÎÂÛÕ ßÏÎÍÑÊÈÕ ÈÍÄÈÂÈÄÎÂ
Ïîëèìîðôèçìû øèðîêî ðàñïðîñòðàíåíû â ïî-
ïóëÿöèÿõ, âêëþ÷àÿ ðåãèîíû, ýòíè÷åñêèå ãðóïïû, à 
òàêæå ñðåäè áîëüíûõ ïàöèåíòîâ. Äëÿ èññëåäîâàíèÿ 
èçìåí÷èâîñòè íóêëåîòèäíûõ ïîñëåäîâàòåëüíîñòåé 
ó íîðìàëüíûõ èíäèâèäîâ ìû âûäåëèëè ãåíîìíóþ 
ÄÍÊ èç êðîâè çäîðîâûõ ÿïîíöåâ è ñåêâåíèðîâàëè 
5މ-íåòðàíñëèðóåìûé ó÷àñòîê (5މ-UTR) ãåíà ôîñôà-
òàçû è ãîìîëîãà òåíçèíà (PTEN), ïðîìîòîðíûå 
ïîñëåäîâàòåëüíîñòè, èíòðîíû è ýêçîíû ãåíîâ p53 
è p14ARF,  èíãèáèòîðà ñóïðåññîðà îïóõîëåâîãî ðîñ-
òà p53 (MDM2) è ãåíîâ ȕ2- è ȕ3-àäðåíîðåöå (-AR). 
Ìû îáíàðóæèëè ïîëèìîðôèçìû â ýòèõ ó÷àñòêàõ,
âêëþ÷àÿ äåëåöèþ â ïîëîæåíèè ñ –465 äî –463,
çàìåíó â ïîëîæåíèÿõ –404 â ãåíå PTEN è –4924 âp 
â ãåíå 14ARF ó íîðìàëüíûõ èíäèâèäîâ. Èíäèâèäû 
ñ ïîëèìîðôèçìîì PTEN è áåç íåãî èìåëè ðàç-
ëè÷íîå ðàñïðåäåëåíèå ïîëèìîðôíûõ âàðèàíòîâ â 
ãåíàõ p53, MDM2 è ȕ3-AR, à òàêæå ñîäåðæàëè 
ïîñëåäîâàòåëüíîñòü àñîöèèðîâàííûõ ïîëèìîðô-
íûõ íóêëåîòèäîâ. Íàøè ðåçóëüòàòû ïîêàçûâàþò 
íàëè÷èå ïîëèìîðôíûõ íóêëåîòèäîâ, âêëþ÷àÿ 
ïîëèìîðôèçì â ãåíå PTEN, ñðåäè çäîðîâûõ ÿïîíñ-
êèõ èíäèâèäîâ, ÷òî îáåñïå÷èâàåò ïåðñïåêòèâíîñòü 
èññëåäîâàíèé ïî ãåíîòèïèðîâàíèþ èíäèâèäîâ è 
ïîïóëÿöèîííûõ èññëåäîâàíèé.
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